Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303419 · ClinicalTrials.gov registry record · NA
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
A NA study, sponsored by GE Healthcare.
- Terminated
- Registry status
- NA
- Development phase
- 224
- Enrollment target
NCT01303419 is a NA study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 224 participants.
The verdict
NCT01303419, a NA study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- NA
- Development phase
- 224 participants
- Enrollment target
Study Summary
Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis. Up to 8 weeks after the CE-BMRI exam, subjects will undergo a Dual Energy Contrast Enhanced Digital Mammograph (DE-CEDM).
Interventions
- DEVICE CE-BMRI
- DEVICE DE-CEDM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01303419
The ClinicalTrials.gov registry entry for NCT01303419 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CE-BMRI is the first listed.
NCT01303419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01303419 about?
NCT01303419 is a clinical study titled "Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer". Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis. Up to 8 weeks after the CE-BMRI exam, subjects will undergo a Dual Energy Contrast Enhanced Digital Mammograph (DE-CEDM).
What is the current status of trial NCT01303419?
This trial is currently terminated. It is a NA study. The enrollment target is 224 participants. The study started on 2010-04. Estimated completion is 2012-06-30.
What interventions are being tested in trial NCT01303419?
The interventions under investigation include: CE-BMRI (DEVICE), DE-CEDM (DEVICE).
Who is sponsoring clinical trial NCT01303419?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.